SCHERING-PLOUGH CEDAX GRAM-POSITIVE/GRAM-NEGATIVE ACTIVE DRUG ON MARKET IN JANUARY; PROMOS MUST INCLUDE FULL INDICATIONS WITH NOTES ON EFFICACY
Schering-Plough's Cedax will be available in January, the company announced Dec. 21. The cephalosporin antibiotic was approved Dec. 20 in both capsules for adults and suspension for children; Cedax was rated "1S" by FDA, denoting a standard review of a new molecular entity.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth